Helios Technologies Announces Retirement of Chief Financial Officer Tricia L. Fulton and Names Sean P. Bagan as Successor
SARASOTA, Fla.–(BUSINESS WIRE)–Helios Technologies, Inc. (NYSE: HLIO) (“Helios” or the “Company”), a global leader in…
News
Ceapro Announces Next Phase of Research Collaboration with the Angiogenesis Foundation
– New studies to focus on speed of healing and molecular profiling of tissue regeneration…
Ceapro Announces Next Phase of Research Collaboration with the Angiogenesis Foundation
– New studies to focus on speed of healing and molecular profiling of tissue regeneration…
Celularity Human Placental-Derived Advanced Biomaterials Demonstrate Superior Biocompatibility and Better Support Differentiated Cell Functions in Studies
Celularity will present benchtop and clinical case studies suggesting the therapeutic potential of its human…
Celularity Human Placental-Derived Advanced Biomaterials Demonstrate Superior Biocompatibility and Better Support Differentiated Cell Functions in Studies
Celularity will present benchtop and clinical case studies suggesting the therapeutic potential of its human…
BioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use Disorder
ANAHEIM, CA, July 18, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – BioCorRx Inc. (OTCQB: BICX)…
BioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use Disorder
ANAHEIM, CA, July 18, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – BioCorRx Inc. (OTCQB: BICX)…
Shockwave Medical Announces Details for Conference Call Discussing Second Quarter 2023 Results and Participation in Upcoming Investor Conference
SANTA CLARA, Calif., July 18, 2023 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a…
Shockwave Medical Announces Details for Conference Call Discussing Second Quarter 2023 Results and Participation in Upcoming Investor Conference
SANTA CLARA, Calif., July 18, 2023 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a…
Revolo Biotherapeutics Announces Additional Data from Phase 2a Trial of ‘1104 in Adults with Active Eosinophilic Esophagitis
– Data shows statistically significant improvement in patient-reported dysphagia symptoms compared to placebo – –…
Revolo Biotherapeutics Announces Additional Data from Phase 2a Trial of ‘1104 in Adults with Active Eosinophilic Esophagitis
– Data shows statistically significant improvement in patient-reported dysphagia symptoms compared to placebo – –…
electroCore Expands Intellectual Patent Portfolio for nVNS Technology
ROCKAWAY, N.J., July 18, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic…
electroCore Expands Intellectual Patent Portfolio for nVNS Technology
ROCKAWAY, N.J., July 18, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic…
Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis
PRECIOSA clinical trial is designed to evaluate efficacy and safety of Grifols Albutein® plus standard…
Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis
PRECIOSA clinical trial is designed to evaluate efficacy and safety of Grifols Albutein® plus standard…
Achieve Life Sciences Announces Presentation at 2023 American Society of Pharmacognosy Annual Meeting
SEATTLE and VANCOUVER, British Columbia, July 18, 2023 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc….
Achieve Life Sciences Announces Presentation at 2023 American Society of Pharmacognosy Annual Meeting
SEATTLE and VANCOUVER, British Columbia, July 18, 2023 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc….
LIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules
PASADENA, CA, July 18, 2023 (GLOBE NEWSWIRE) — LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and…
LIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules
PASADENA, CA, July 18, 2023 (GLOBE NEWSWIRE) — LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and…
LianBio Partner NANOBIOTIX Enters into License Agreement with Janssen for Radioenhancer NBTXR3, with LianBio Retaining Development and Commercialization Rights in Greater China, South Korea, Singapore and Thailand
SHANGHAI, China and PRINCETON, N.J., July 18, 2023 (GLOBE NEWSWIRE) — LianBio (Nasdaq: LIAN), a…